Virtus ETF Advisers LLC Acquires 33,029 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Virtus ETF Advisers LLC grew its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 115.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 61,668 shares of the biopharmaceutical company's stock after buying an additional 33,029 shares during the quarter. Virtus ETF Advisers LLC owned 0.10% of Sage Therapeutics worth $335,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Geode Capital Management LLC raised its position in Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock valued at $8,975,000 after buying an additional 3,757 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Sage Therapeutics by 57.7% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 8,228 shares during the last quarter. Inspire Investing LLC raised its holdings in shares of Sage Therapeutics by 30.4% in the fourth quarter. Inspire Investing LLC now owns 75,313 shares of the biopharmaceutical company's stock valued at $409,000 after purchasing an additional 17,541 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Sage Therapeutics in the fourth quarter worth $91,000. Finally, Ieq Capital LLC acquired a new position in Sage Therapeutics during the fourth quarter worth $57,000. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on SAGE. Wedbush reissued a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a research report on Wednesday, February 12th. HC Wainwright reiterated a "neutral" rating and set a $12.00 target price (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Bank of America began coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 price target for the company. Canaccord Genuity Group dropped their price objective on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Sage Therapeutics has a consensus rating of "Hold" and an average price target of $8.81.

Sage Therapeutics Price Performance

Sage Therapeutics stock traded down $0.18 during trading hours on Friday, hitting $7.30. The company had a trading volume of 1,060,063 shares, compared to its average volume of 1,221,130. The firm has a 50-day moving average of $7.54 and a 200 day moving average of $6.78. The firm has a market cap of $457.13 million, a PE ratio of -1.11 and a beta of 0.20. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $14.31.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). The firm had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Sage Therapeutics's revenue for the quarter was up 78.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.80) EPS. As a group, research analysts expect that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.